Work

The effectiveness of Rosuvastatin in controlling LDL-C and non-HDL-C levels in hypertensive patients with or without diabetes mellitus

Year: 2025

Type: article

Abstract: BackgroundLDL-c and non-HDL-c are contributing risk factors in the development of cardiovascular disease and stroke, exacerbating hazardous cardiovascular events. Rosuvastatin is a widely used statin globally, and a thorough assessment of its efficacy and safety in hypertensive patients with or without diabetes mellitus is essential.ObjectivesThis study aims to compare the efficacy of Rosuvastatin 20mg in controlling LDL-c and non-HDL-c in hypertensive patients with and without diabetes.MethodsA cross-sectional descriptive study on 126 primary hypertensive patients (72 hypertensive patients with diabetes and 54 hypertensive patients without diabetes) treated with Rosuvastatin based on cardiovascular risk stratification according to SCORE to assess the efficiency of achieving treatment targets.ResultsIn hypertensive patients without diabetes (n=54; 42.9%), the average age was higher (63.52 ± 8.68 years) and predominantly female (70.4%) compared to those with diabetes (n=72; 57.1%). After 12 weeks of Rosuvastatin 20mg treatment, non-diabetic patients exhibited more significant improvements in lipid profiles, notably marked decreases in LDL-c and non-HDL-c levels (p<0.001). Treatment targets for LDL-c and non-HDL-c were achieved by 20.4% and 41.5% of non-diabetes, and 27.8% and 40.3% of diabetes, respectively. History of stroke and coronary artery disease was significantly associated with increased LDL-c and non-HDL-c in both pre-and post-treatment in both groups.ConclusionThe utilization of Rosuvastatin 20mg has shown efficacy in ameliorating elevated LDL-c and non-HDL-c levels in primary hypertensive patients. Specifically, in the hypertensive group without diabetes, Rosuvastatin 20mg aids in better control of LDL-c and non-HDL-c compared to the hypertensive group with diabetes.

Source: Endocrine and Metabolic Science

DOI: 10.1016/j.endmts.2025.100230